文献速递头颈部肿瘤放疗放疗物理与技术

非黑色素瘤皮肤癌放疗后美容评估工具与方法的系统综述

Skin Cosmesis assessment tools and methods in patients with non-melanoma skin cancers treated with radiotherapy: Systematic review on behalf of the ESTRO skin and soft tissue focus group and the GEC-ESTRO head and neck and skin working group.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-06-25

本系统综述由ESTRO皮肤与软组织焦点组及GEC-ESTRO头颈与皮肤工作组完成,纳入85项研究共17,231例患者,旨在综合非黑色素瘤皮肤癌放疗后美容评估的报告方式。结果显示美容评估方法异质性大、主观性强且分级简化,评估条目以色素改变和毛细血管扩张为主,评估时间点报告不一致。

要点

  • 美容评估方法异质性大,25/63项研究细节不足以重复评估。
  • 常用评估条目为色素改变(87.3%)和毛细血管扩张(84.1%)。
  • 51.8%的研究未明确美容评估时间点,晚期评估多超过12个月。

核心结论

  • 现有非黑色素瘤皮肤癌放疗后美容评估工具异质性大、主观性强且分级简化,亟需标准化前瞻性报告框架。

研究设计与样本

  • 系统综述(PROSPERO: CRD420251020168),检索MEDLINE、Embase和Web of Science,纳入报告非黑色素瘤皮肤癌放疗后美容评估的原始研究85项,共17,231例患者,治疗年份1955-2023。

主要发现

  • 85项研究中72项(85.0%)为回顾性研究;22项(25.9%)未指定美容分级;63项详述评估方法,其中25项细节不足以重复评估。
  • 美容评估条目包括色素改变(87.3%)、毛细血管扩张(84.1%)、畸形(66.6%)、皮肤萎缩和纤维化(60.3%)及脱毛(33.3%)。
  • 25项记录报告急性(<90天)美容评估,35项报告晚期(>90天)评估,其中32/35项晚期评估超过12个月;44项(51.8%)未指定评估时间点。

关键数值与推荐

  • 分别有3、26、18、2和15项研究采用2、3、4、5和6级美容分级;22项(25.9%)未指定美容分级。

临床怎么用

  • 临床报告美容结局时应明确评估工具、分级和评估时间点,优先采用经验证的美容评估框架以提高可比性。

局限性

  • 纳入研究以回顾性为主(72/85,85.0%),美容评估方法异质性大、主观性强且分级简化,部分研究细节不足以重复评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-melanoma skin cancers (NMSC) are highly prevalent and rarely impact mortality; post-treatment cosmesis is paramount as the sequelae of treatment are outwardly visible. There is no agreement on reporting of post-treatment cosmesis, thereby precluding standardised comparisons between treatment modalities. We conducted this systematic review (PROSPERO: CRD420251020168) on behalf of the ESTRO Skin and Soft Tissue Focus Group and the Head and Neck and Skin GEC-ESTRO Working Group to synthesise data on how cosmesis is reported. MEDLINE, Embase, and Web of Science were searched for original studies including cosmesis assessment following radiotherapy for NMSC. Data was collated on the methodology, cosmesis assessment items, and assessment timeframe. Eighty-five studies were included, comprising 17,231 patients treated 1955-2023. Most studies were retrospective (72;85.0%). Three, 26, 18, 2, and 15 studies employed 2, 3, 4, 5, and 6 cosmesis grades; 22 (25.9%) studies did not specify cosmesis grade. Cosmesis assessment methodology was detailed in 63 studies; 25/63 provided insufficient detail to replicate the assessment. Cosmesis assessment items: pigmentation change (87.3%), telangiectasia (84.1%), deformity (66.6%), skin atrophy and fibrosis (60.3%), and epilation (33.3%). Acute (<90d) cosmesis was reported by 25 records, late (>90d) in 35 records, with 32/35 late assessments reporting cosmesis beyond 12 months; 44 (51.8%) did not specify assessment timeframe. The identified skin cosmesis assessments are limited by heterogeneity, subjectivity, and simplified compound grades. Prospective reporting will capture the temporal changes within a newly developed granular and validated skin cosmesis reporting framework.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Mir R, Miszczyk M, Krzysztofiak T, et al. Skin Cosmesis assessment tools and methods in patients with non-melanoma skin cancers treated with radiotherapy: Systematic review on behalf of the ESTRO skin and soft tissue focus group and the GEC-ESTRO head and neck and skin working group. Clin Transl Radiat Oncol. 2026. PMID: 42404298. doi:10.1016/j.ctro.2026.101222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。